New York, New York-- (Newsfile Corp. - January 28, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) for potential ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

Scorpion alleged the company operates a "mafia-style" scheme involving off-label device misuse and customer attrition, as it set TransMedics target price of $0. “Investors sense something is ...

TransMedics (TMDX) Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion Capital on January 10. In response, the company issued the ...

Shares of organ transplant innovator TransMedics Group ( TMDX -1.41%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...

Scorpion Capital has assigned a target price of $0 to TransMedics stock, suggesting the firm believes the company's alleged misconduct poses an existential threat. Hagens Berman's Investigation of ...

TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion Capital on Jan. 10, 2025, stating them as inaccurate and misleading.

Last Friday, Scorpion Capital published a 342-page short report -- yes, 342 pages! -- detailing an alleged six-month investigation into TransMedics and its business practices. TransMedics has ...

Shares of TransMedics, Group Inc. (NASDAQ: TMDX) suffered a sharp decline over the past two trading days following the release of a damaging report by activist short-seller Scorpion Capital.